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The cyclopentapeptide CXCR4 antagonist FC131 (cyclo(-Arg1-Arg2-2-Nal3-Gly4-D-Tyr5-), 2; 2-Nal = 3-
(2-naphthyl)alanine) represents an excellent starting point for development of novel drug-like ligands 
with therapeutic potential in HIV, cancer, stem-cell mobilization, inflammation, and autoimmune 
diseases. While the structure-activity relationships for Arg1, Arg2, and Gly4 are well established, less is 10 
understood about the roles of the aromatic residues 2-Nal3 and D-Tyr5. Here we report further structure-
activity relationship studies of these two positions, which showed that (i) the distal aromatic ring of the 2-
Nal3 side chain is required in order to maintain high potency, and (ii) replacement of D-Tyr5 with 
conformationally constrained analogues results in significantly reduced activity. However, a simplified 
analogue that contained Gly instead of D-Tyr5 was only 13-fold less potent than 2, which means that the 15 
D-Tyr5 side chain is dispensable. These findings were rationalized based on molecular docking, and the 
collective structure-activity data for the cyclopentapeptides suggest that appropriately designed Arg2-2-
Nal3 dipeptidomimetics have potential as CXCR4 antagonists.
Introduction 
By now, the role of the G protein-coupled C-X-C chemokine 20 
receptor 4 (CXCR4) in HIV, cancer, stem-cell mobilization, 
inflammation, and autoimmune diseases is well established,1 and 
several different antagonists for CXCR4 – both peptides and non-
peptides – have been described in the literature over the last two 
decades.2 The prototype non-peptide antagonist plerixafor 25 
(AMD3100), which is administered by subcutaneous injection, 
was approved for stem-cell mobilization in 2008 and is currently 
the only marketed CXCR4 antagonist. The molecular 
pharmacology of AMD31003, 4 and the structurally related non-
peptide antagonists AMD34655 and AMD110706 has been 30 
extensively characterized.7 
 The majority of the reported peptide antagonists has been 
developed by Fujii and co-workers, starting from the 18-mer 
synthetic polyphemusin II analogue T22.8 Extensive structure-
activity relationship (SAR) and downsizing studies first led to the 35 
potent 14-mer antagonist T140 (1, Fig. 1),9 and eventually to the 
discovery of the cyclopentapeptide FC131 (2, Fig. 1),10 which we 
are currently using as lead compound for our ongoing efforts 
toward peptidomimetic CXCR4 antagonists. A 16-mer analogue 
of 1 that contains two additional C-terminal residues (CVX15, 3, 40 
Fig. 1) was recently reported by Wu et al. as the ligand in an X-
ray co-crystal structure of CXCR4.11 Interestingly, the potent 
peptide antagonists 1–3 share an Arg1-Arg2-(n-Nal)3-Xaa4-L-/D-
Tyr5 pentapeptide motif (Fig. 1), a notable difference being that 1 
and 2 both contain 3-(2-naphthyl)alanine (2-Nal) in position 3 45 

































Figure 1 Structure of the lead cyclopentapeptide CXCR4 antagonist 
FC131 (2) and sequences of the larger peptide antagonists T140 (1) and 
CVX15 (3). The conserved Arg1-Arg2-(n-Nal)3-Xaa4-L-/D-Tyr5 50 
pentapeptide motif is shown in bold, and the aromatic positions 3 and 5 
are highlighted with grey background. Cit = citrulline; 1-Nal = 3-(1-
naphthyl)alanine; 2-Nal = 3-(2-naphthyl)alanine. 
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 Aromatic rings and charged groups in ligand side chains have 
consistently been found to play a special role in binding and 
activation of peptidergic GPCRs.12 Several SAR studies of the 
cyclopentapeptide 2 (Fig. 1) have been reported, and the relative 
importance of the two arginine residues is now well established: 5 
Arg2 is crucial and serves as the anchor point for receptor 
binding, while Arg1 plays a less important role.13-15 The Gly 
residue in position 4 was originally introduced for synthetic 
reasons,10 but a subsequent SAR study showed that the activity 
was reduced when Gly4 was replaced with α-substituted nonpolar 10 
residues;16 thus, the conformational and/or steric properties of 
Gly4 are beneficial. In contrast, existing SAR data for the two 
aromatic residues 2-Nal3 and D-Tyr5 are less informative. 
Importantly, in a previously reported alanine scan of 2, the Ala3 
and D-Ala5 analogues were both classified as inactive (IC50 > 1 15 
µM in both cases).14 Consequently, the side chains of 2-Nal3 and 
D-Tyr5 were both considered as pharmacophoric elements for 
cyclopentapeptide CXCR4 antagonists. However, the roles and 
relative importance of the 2-Nal3 and D-Tyr5 side chains have 
been unclear, which has led to some ambiguity in pharmacophore 20 
definitions, i.e. whether one or both aromatic side chains are 
required for antagonistic activity.17, 18 
 On this background, we have performed further SAR studies 
of the two aromatic positions in the lead cyclopentapeptide 2. 
Based on the nature of the already existing SAR data, two 25 
different approaches were used: for position 3 a classical SAR 
study, and for position 5 the introduction of conformational 
rigidity/flexibility. Here we report the findings of these SAR 
studies, an interpretation of the data based on molecular docking, 
and the implications for design of novel peptidomimetic CXCR4 30 
antagonists. 
Results and discussion 
Design and SAR for position 3 
In addition to the Ala3 analogue that was classified as inactive,14 
only five analogues have previously been reported for position 3 35 
(2-Nal). Inversion of stereochemistry (D-2-Nal3) resulted in more 
than 25-fold reduction in affinity,10 which shows that L-
configuration is optimal in this position. Substitution with 
tryptophan (Trp3) or a sulphur-containing Trp-analogue (3-
(benzothiazol-2-yl)alanine; Bth3) were in both cases shown to 40 
result in good activity,14 which could be expected based on the 
structural similarity with 2-Nal. In contrast, N-methylation (N-
Me-2-Nal3) was shown to significantly reduce the antagonistic 
activity,16 while introduction of a conformationally constrained 
Trp-derivative resulted in an inactive compound.14 45 
 However, analogues with aromatic side chains that are 
significantly different from 2-Nal have not previously been 
reported for this position. For the SAR study in position 3, we 
therefore replaced 2-Nal with aromatic and aliphatic residues of 
different size and shape, giving a compound series that contained 50 
small (4–6), medium (7–10), and large (11, 12) side chains (Fig. 
2). For reference purposes the known Ala3 analogue 1314 was also 
included. Our synthetic strategy for preparation of 
cyclopentapeptide ligands and the biological assay for 
determination of antagonistic potency have recently been 55 
described.15 
 The analogues 4–13 were all significantly less potent than 2 
(EC50 = 0.40 µM) (Fig. 2). The most potent compound was the 
isomeric 1-Nal3 analogue 10 (EC50 = 5.6 µM, 14-fold reduction in 
potency), and the only compounds with activity (EC50 < 100 µM) 60 
contained a medium-sized substituent (2 > 10 > 9, 8, 7). Thus, the 
present SAR data show that position 3 of the cyclopentapeptides 
is very sensitive toward substitutions, and that 2-Nal remains the 
best residue in this position. 
O
4 (Phg3): >100 µM
10 (1-Nal3): 5.6 µM
6 (Cha3): >100 µM
9 (Bsa3): 19 µM
5 (Phe3): >100 µM
8 (Hch3): 29 µM
12 (Bph3): >100 µM11 (Pph3): >100 µM
7 (Hph3): 31 µM
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Figure 2 Structures and antagonistic potencies (EC50) of the lead 
cyclopentapeptide 2 and the synthesized Xaa3 analogues 4–13. 
 Interestingly, Fujii et al. have previously reported a SAR study 
in the corresponding position 3 of the parent 14-mer peptide 
antagonist 1 (Fig. 1),19 which showed that the Phe3 analogue was 70 
only 6-fold less active than the 2-Nal3 analogue (1), and 7-fold 
more active than the 1-Nal3 analogue. This is in contrast to the 
present findings, where the Phe3 analogue 5 was inactive, 
meaning that the main contribution comes from the distal 
aromatic ring of 2-Nal3. Thus, the SAR trends obtained for the 75 
larger peptide scaffold 1 cannot automatically be transferred to 
the cyclopentapeptide scaffold of 2. Moreover, the CXCR4 co-
crystal peptide ligand 3 (Fig. 1) contains 1-Nal3 instead of 2-Nal3, 
while still being very potent (IC50 = 0.6 nM).11 Thus, the present 
SAR data indicates that the 2-Nal3 side chain of 2 approaches its 80 
subpocket in a different way than the corresponding side chain of 
the larger peptides 1 and 3. 
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Design and SAR for position 5 
For position 5 (D-Tyr), a larger number of cyclopentapeptide 
analogues have been reported in the literature.14, 16, 20, 21 The L-
Tyr5 epimer was shown to be 35-fold less active than 2,10 
meaning that the stereochemistry in this position is optimized. 5 
Regarding size, the smaller D-phenylglycine (D-Phg5) analogue 
was shown to have low affinity,21 while the larger D-
naphthylalanine analogues had reduced affinity (D-1-Nal5 >> D-
2-Nal5),20 which shows that D-Tyr is the optimal size in position 
5. Removal of the 4-hydroxyl group in D-Tyr5 to give the D-Phe5 10 
analogue resulted in a 6-fold reduction in affinity,14 while 
introduction of a halogen on the phenyl ring led to further affinity 
reduction.21 Similarly, replacement of the 4-hydroxyl group with 
a 4-amino or a 4-methoxy group resulted in 13-fold and 64-fold 
reduction in affinity, respectively.14  Overall, the reported phenyl-15 
substituted analogues can be ranked by affinity as follows: 4-OH 
(2) > H > 2-F > 3-F > 4-NH2 > 4-F > 4-OMe > 4-Cl > 4-Br. 
 Rational design of optimized ligands not only requires 
identification of the pharmacophoric groups, but also knowledge 
of the spatial orientation of these. For D-Tyr the global 20 
orientation of the side chain is described by the χ1 torsion angle 
(Fig. 3), which can adopt three low-energy conformations: trans, 
gauche-(+), and gauche-(-). Our own pharmacophore modelling17 
and docking studies15 of 2 and analogues suggest that χ1 of D-
Tyr5 adopts the trans conformation (χ1 ≈ 180˚) in the receptor-25 
bound conformation, while docking studies by Demmer et al. 
suggest the gauche-(-) conformation (χ1 ≈ −60˚).22 However, SAR 
studies that address the rotameric state of the D-Tyr5 side chain in 
the receptor-bound conformation of 2 have not been reported. We 
therefore designed a series of cyclopentapeptide analogues that 30 
contained conformational constraints in position 5. Since it was 
known that D-Tyr5 could be replaced with D-Phe5 without a 
drastic change in activity,14 we used a series of constrained D-Phe 
mimetics (15–18, Fig. 3) instead of the corresponding 
hydroxylated D-Tyr mimetics, which were commercially 35 
unavailable. Thus, the known D-Phe analogue 1414 was used as 
the reference compound for this compound series; in our assay, 
14 (EC50 = 0.85 µM) was approximately 2-fold less potent than 2 
(EC50 = 0.40 µM), which reflects the contribution from the 4-
hydroxyl group of D-Tyr5. 40 
 In compound 15, the phenyl ring was linked to Cα via a 
methylene group using the achiral 2-aminoindan-2-carboxylic 
acid (Aic5) as building block. When considered as a D-Phe 
mimetic, χ1 of Aic has approximately the same preference for the 
gauche-(+) and trans conformations, while the gauche-(-) 45 
conformation is unavailable.23 Introduction of this amino acid 
(15) resulted in a 87-fold reduction of potency (EC50 = 74 µM) 
compared to 14. In compound 16, the phenyl ring was instead 
linked to Nα using 1,2,3,4-tetrahydroisoquinoline-3-carboxylic 
acid (D-Tic5). D-Tic is a chimera of D-Phe and D-pipecolic acid 50 
(D-Pic) where χ1 can adopt the two gauche conformations, but 
not the trans conformation.23 Compound 16 (EC50 = 25 µM) was 
29-fold less potent than 14; this is consistent with data for the 
corresponding hydroxylated D-Tyr mimetic D-Tic(7-OH)5, which 
resulted in a 20-fold reduction in activity compared to 2.14 For the 55 
two final compounds in this series (17 and 18), we wanted to 
introduce 3-phenyl-D-Pro (D-Ppr), which exists as two 
diastereomers (3S- or 3R-configuration). D-Ppr is a chimera of D-
Phe and D-Pro where χ1 can access the trans conformation and 
one of the two gauche conformations (depending on which 60 
diastereomer that is used), but favours trans over gauche.23 Since 
the enantiomerically pure (3S)-D-Ppr and (3R)-D-Ppr were 
commercially unavailable, racemic trans-Ppr (containing (3S)-D-
Ppr and (3R)-L-Ppr) and cis-Ppr (containing (3R)-D-Ppr and (3S)-
L-Ppr) were used as building blocks. The resulting compounds 17 65 
and 18 (mixtures of two diastereomers, see ESI) were 
approximately equipotent, but still more than 40-fold less potent 
than 14. Due to the relatively low activity of the diastereomeric 
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Figure 3 Structures and antagonistic potencies (EC50) of the lead 
cyclopentapeptide 2 and the synthesized Xaa5 analogues 14–22, also 
showing the χ1 torsion angle of D-Tyr5 for 2. 
 It was expected that one of the constrained analogues 15–18 75 
would be significantly more potent than the others, reflecting the 
correct orientation of χ1. However, all analogues showed 
moderate to low activity, which makes it difficult to draw any 
conclusions about the rotameric state for D-Tyr5 in the receptor-
bound conformation of 2. Clearly, the beneficial effect of 80 
constraining χ1 is outweighed by the simultaneous introduction of 
other structural elements that lead to unfavorable receptor 
interactions. First, introduction of 1-2 additional methylene 
groups leads to an increased steric demand, which the binding 
subpocket may not be able to accommodate. Second, Aic and D-85 
Tic (15 and 16) not only constrain the χ1 torsion angle, but also 
the χ2 angle, which determines the plane of the phenyl ring. 
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Third, Nα-alkylation (16-18) removes the H-bond donor 
properties of the amide bond. Fourth, all the constrained D-Phe 
mimetics (15–18) will affect the backbone conformation: α,α-
disubstituted amino acids (15) are known to stabilize/induce a 
helical backbone conformation,24 while cyclic amino acids based 5 
on D-Pic and D-Pro (16-18) restrict the φ backbone torsion and 
promote trans/cis isomerization of the preceding amide bond.25 In 
order to isolate the backbone effects imposed by D-Tic (16) and 
D-Ppr (17 and 18), we prepared the D-Pic5 and D-Pro5 analogues 
19 and 20 as well as the known D-Ala5 analogue 2114 (Fig. 3). 10 
Compounds 19 and 20 failed to produce any antagonistic activity 
(EC50 > 100 µM), while 21 was moderately active (EC50 = 51 
µM), which confirms that the backbone effects are partly 
responsible for the relatively low potency of 16–18. These 
findings are consistent with data for the N-methylated analogue 15 
(N-Me-D-Tyr5), which resulted in a 32-fold reduction in activity 
compared to 2.16 Realizing that introduction of conformational 
constraints in position 5 was counterproductive, we went in the 
opposite direction and prepared the Gly5 analogue 22 (Fig. 3). 
Interestingly, this simplification resulted in an EC50 value of 5.1 20 
µM, i.e., a 10-fold increase in potency compared to 21 and only a 
6-fold reduction relative to 14. Thus, the reduced size and/or the 
increased conformational flexibility of Gly5 partly compensates 
for the side chain removal. Consequently, we do not longer 
consider the D-Tyr5 side chain as an essential pharmacophoric 25 
element for cyclopentapeptide CXCR4 antagonists. 
Rationalization of SAR for the two aromatic positions in 
terms of receptor binding 
The sequence similarity between the 16-mer 3 and the 
cyclopentapeptide 2 (Fig. 1) suggests that the binding mode for 2 30 
can be inferred from the co-crystal structure of 3 and CXCR4 
(PDB code 3OE0).11 However, inspection of this structure shows 
that the distance between Arg1 and Tyr5 in the receptor-bound 
conformation of 3 is not compatible with head-to-tail cyclization, 
which is required for 2. This means that the position of some side 35 
chains in 2 must be shifted relative to the corresponding side 
chains in 3. The crystal structure further shows that the aromatic 
side chains in positions 3 (1-Nal) and 5 (Tyr) of 3 are both 
located in hydrophobic regions around transmembrane helix 
(TMH) 5; 1-Nal3 at the bottom of the pocket, and Tyr5 higher up, 40 
close to the extracellular loop between TMHs 4 and 5. 
 In order to rationalize the present SAR data for the aromatic 
positions 3 and 5 in cyclopentapeptide ligands, compounds 2, 14, 
and 22 were docked to this X-ray structure using an optimized 
docking protocol as recently described.15 Specifically, based on 45 
preliminary site-directed mutagenesis studies that identified 
Asp171 in TMH4 as important for the activity of 2,26 a H-bond 
constraint was placed on Asp171 to reduce the number of 
irrelevant poses. Moreover, Arg188 in extracellular loop 2 was 
temporarily mutated to alanine since the side chain partly 50 
restricted access to the sub-pocket containing Asp171. 
 
  
Figure 4 Proposed binding mode for the lead cyclopentapeptide 2: (A) 
3D representation showing the seven transmembrane helices (TMHs 1-7; 55 
coloured ribbons) and the binding pocket (grey surface; receptor atoms 
within 5 Å of the ligand) and selected key interactions; (B) 2D 
representation detailing the intermolecular interactions. 
 The docked ligands only differ in position 5 (2: D-Tyr5; 14: D-
Phe5; 22: Gly5), and only minor differences were seen among 60 
their top scoring poses (data not shown); thus, they can be 
collectively represented by the binding mode for 2 (Fig. 4). The 
2-Nal3 side chain is accommodated in a well-defined hydrophobic 
subpocket mainly composed of residues in TMH 5 (Fig. 4A). The 
restrictions of this subpocket would explain the reduced potency 65 
of the Xaa3 analogues 4–13. In contrast, the side chain in position 
5 (2: D-Tyr5; 14: D-Phe5) is located at the opposite side of the 
transmembrane bundle, near the top of TMH 1, where it interacts 
with residues in the extracellular N-terminal fragment of CXCR4 
(Fig. 4A). A favourable cation-π interaction is seen between the 70 
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guanidino group of Arg30 and the phenyl ring of D-Tyr5 (2) or D-
Phe5 (14); the 4-hydroxyl group of 2 forms an additional H-bond 
with Glu32 (Fig. 4B), which would explain its higher activity. 
Still, the phenyl ring of 2 and 14 is located in a relatively open 
region and is partially solvent exposed (Fig. 4B), which 5 
represents an unfavourable contribution to binding. Overall, the 
favourable contributions outweigh the unfavourable, but the lack 
of a defined subpocket for Xaa5 would explain why the D-Tyr5 
side chain can be removed without a dramatic loss of potency 
(22: Gly5). 10 
 We have recently described the interactions between the two 
Arg residues and the receptor in detail;15 briefly, the essential 
Arg2 side chain sits deeply between TMHs 3 and 4, while the less 
important Arg1 side chain is located higher up and points into a 
partly open region around TMH 2. When considering the entire 15 
cyclopentapeptide ligand, a general picture emerges where the 
Arg2-2-Nal3 fragment is buried in the major binding pocket 
(composed of TMHs 3, 4, 5, and 6), while the D-Tyr5-Arg1 
fragment is located higher up in the minor binding pocket 
(composed of TMHs 1, 2, 3, and 7) and is partially solvent 20 
exposed. However, it should be noted that the Asp171-constraint 
used to generate these poses is based on preliminary site-directed 
mutagenesis data for 2, and that alternative binding modes have 
been suggested.27 Thus, further experimental studies are needed 




All reagents and solvents were purchased and used as received. 
The individual amino acids were all Nα-Fmoc protected, and 30 
pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl (Pbf) and t-Bu 
were used as protecting groups for the Arg and D-Tyr side chains, 
respectively. Preparative HPLC was performed with an 
XBridge™ C18 reversed phase column (250 mm × 19 mm, 10 
µm particle size) on a Waters 600 Semi Prep System. Analytical 35 
HPLC was performed with an XBridge™ C18 reversed phase 
column (250 mm × 4.6 mm, 5 µm particle size) on a Waters 2695 
system. Different gradients of CH3CN-H2O, containing 0.1% 
TFA, were used as eluting solvent for both preparative and 
analytical HPLC (flow rates of 15 mL/min and 1 mL/min, 40 
respectively), with photodiode array detection at 214 or 254 nm. 
HRMS spectra were obtained on an LTQ Orbitrap XL. 1H and 
13C NMR spectra were recorded on a 400 MHz Varian 
spectrometer. Chemical shifts are expressed in ppm relative to 
methanol (1H 3.31 ppm, 13C 49.0 ppm). Coupling constants are 45 
given in hertz (Hz) and the values are given in δ scale. 
Chemistry 
The target compounds 4–22 were synthesized as recently 
described for 2.15 Briefly, the linear pentapeptide precursor was 
synthesized by standard Fmoc-based solid-phase peptide 50 
synthesis using a preloaded Fmoc-Gly Novasyn TGT resin. After 
cleavage from the resin, the linear side chain protected 
pentapeptide was cyclized head-to-tail in dilute solution to give 
the side chain protected cyclopentapeptide. Following 
deprotection, the crude peptide was purified by preparative HPLC 55 
and lyophilized to give the final products 4–22 as 
di(trifluoroacetate) salts. The identity of all final products was 
confirmed by HRMS and NMR, and all compounds were >95% 
pure as determined by analytical HPLC, see ESI. 
Biology 60 
The antagonistic potency of 4–22 was determined as recently 
reported for 2; see ref. 12 for a detailed description. Briefly, the 
compounds were tested in a functional assay that measured 
inhibition of CXCL12-induced activation of human CXCR4, 
which was transiently expressed in COS-7 cells. Compounds 4–65 
12 were tested in the range 10–10–10–5 M, and the EC50 values 
were calculated by extrapolation of the curve under the 
assumption that the Hill coefficient was –1 and that the 
compounds were full antagonists. The other compounds were 
tested in the range 10–8–10–4 M under the same assumptions. 70 
Computational studies 
The cyclopentapeptide ligands 2, 14, and 22 were docked to the 
CXCR4 structure using Schrödinger’s induced fit docking 
workflow28 as recently described.15 Briefly, the X-ray co-crystal 
structure of human CXCR4 and the 16-mer peptide antagonist 75 
CVX15 (PDB code 3OE0)11 was prepared for docking using the 
Protein Preparation Wizard workflow.29 The three ligands were 
docked to this structure using our optimized protocol,15 and the 
top 10 poses within an energy window of 30 kcal/mol were kept 
for each ligand. Visual inspection of the 30 generated poses 80 
resulted in the identification of the common binding mode for 2, 
14, and 22 that is discussed above. 
Conclusions 
The SAR data presented here clearly show that the naphthyl 
group in position 3 is more important for activity than the phenol 85 
group in position 5 (13 vs 21), and that the distal aromatic ring of 
the 2-Nal3 side chain is critical in order to maintain potency. The 
collective SAR data for the cyclopentapeptide CXCR4 
antagonists, supported by molecular modeling, indicate that the 
Arg2 and 2-Nal3 side chains are buried in the receptor, while the 90 
side chains of D-Tyr5 and Arg1 are partly solvent exposed. In 
terms of peptidomimetic design, Arg2-2-Nal3 seems to serve as a 
minimal recognition motif, meaning that appropriately designed 
dipeptidomimetics have potential as CXCR4 antagonists. 
Tripeptidomimetic ligands based on the Arg1-Arg2-2-Nal3 95 
fragment represent an intermediary step along this path, and we 
are currently pursuing such compounds. 
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